Results 181 to 190 of about 82,766 (300)

Biochemical basis of novel antiplatelet drugs

Journal of Clinical and Scientific Research, 2019
Paresh P Kulkarni, Debabrata Dash
doaj   +1 more source

The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study. [PDF]

Front Neurol
Liu X, Zhong G, Gu H, Wen Y, Zhong X, Zhang J, Xie Y.   +6 more
europepmc   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Does dutasteride reduce the bleeding in transurethral resection of the prostate in patients on antiplatelet drugs? [PDF]

Curr Urol
Rammah AM, Meshref A, Soliman E, Abd Elaziz IN, Habib E, Abdelaziz AY, Abozamel AH.   +6 more
europepmc   +1 more source

Influence of Oral Anticoagulation and Antiplatelet Drugs on Outcome of Elderly Severely Injured Patients. [PDF]

J Clin Med, 2021
Kerschbaum M, Lang S, Henssler L, Ernstberger A, Alt V, Pfeifer C, Worlicek M, Popp D.   +7 more
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Real-world analysis of characteristics and guideline adherence of antiplatelet drugs prescriptions among patients with coronary artery disease and its comorbidities: a cross-sectional study. [PDF]

BMC Cardiovasc Disord
Lu T, Yang Z, Zhang P, Zhu H, Chu Q, Jing L, Sun W, Shi J.   +7 more
europepmc   +1 more source

ALOX15 mediates thrombin‐induced myristoylation, trafficking, and interaction of protease‐activated receptors, leading to platelet activation and hemostasis

The FEBS Journal, EarlyView.
The role of PARs in platelet function is fairly known; however, the underlying mechanisms are not fully understood. We report that thrombin myristoylates PAR4 in mouse platelets and PAR1 and PAR4 in human platelets, facilitating their membrane transport and interaction, leading to PAR3/4 heterodimers in mice and PAR1/4 heterodimers in humans.
Suresh Govatati, Chandra Sekhar Yadavalli, Md Monirul Hoque, Swapna Thota, Gadiparthi N. Rao   +4 more
wiley   +1 more source

Antiplatelet drugs block platelet activation by VITT patient serum.

Blood, 2021
Smith CW, Montague SJ, Kardeby C, Di Y, Lowe GC, Lester WA, Watson SP, Nicolson PLR.   +7 more
europepmc   +1 more source

Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. [PDF]

BMC Neurol, 2021
Del Giovane C, Boncoraglio GB, Bertù L, Banzi R, Tramacere I.   +4 more
europepmc   +1 more source